Dermatology
On demand events

ADVENT Forum 2025 On Demand page

Watch on-demand expert soundbites recorded at the April 2025 ADVENT Forum in Lisbon, Portugal, featuring dermatology and immunology perspectives on mechanisms and clinical practice. Topics range from disease mechanism to patient care and quality of life, spanning atopic dermatitis (AD), prurigo nodularis (PN), chronic spontaneous urticaria (CSU) and bullous pemphigoid (BP).

On demand materials

IL-4 Is the Primary Cytokine That Drives Th2 Cell Polarization and Amplifies Type 2 Inflammation
Type 2 Inflammation
expert video

IL-4 Is the Primary Cytokine That Drives Th2 Cell Polarization and Amplifies Type 2 Inflammation

How Does Type 2 Inflammation Manifest in Chronic Diseases Across Different Organs?
Type 2 Inflammation
expert video

How Does Type 2 Inflammation Manifest in Chronic Diseases Across Different Organs?

Type 2 Inflammatory Diseases Can Negatively Impact Patients and Their Caregivers
Type 2 Inflammation
expert video

Type 2 Inflammatory Diseases Can Negatively Impact Patients and Their Caregivers

Distinct Mechanisms Drive Inflammation and Itch in Chronic, Type 2 Inflammatory Diseases
Type 2 Inflammation
expert video

Distinct Mechanisms Drive Inflammation and Itch in Chronic, Type 2 Inflammatory Diseases

Itch in Prurigo Nodularis
Dermatology
expert video

Itch in Prurigo Nodularis

Type 2 Cytokines Have Multiple Critical Roles in BP That Contribute to Inflammation and Itch
Dermatology
expert video

Type 2 Cytokines Have Multiple Critical Roles in BP That Contribute to Inflammation and Itch

Type 2 Cytokines Have Multiple Critical Roles in BP That Contribute to Inflammation and Itch
Dermatology
expert video

Type 2 Cytokines Have Multiple Critical Roles in BP That Contribute to Inflammation and Itch

Atopic and Nonatopic Comorbidities in AD and the Importance of Early Intervention
Dermatology
expert video

Atopic and Nonatopic Comorbidities in AD and the Importance of Early Intervention

Atopic Dermatitis and the Risk of Developing Other Atopic Diseases
Dermatology
expert video

Atopic Dermatitis and the Risk of Developing Other Atopic Diseases

Coexisting Type 2 Inflammatory Diseases Can Add to the Patient Overall Disease Burden
Type 2 Inflammation
expert video

Coexisting Type 2 Inflammatory Diseases Can Add to the Patient Overall Disease Burden

Type 2 Inflammatory Disease: What Are the Mechanisms that Contribute to the Development of Other Atopic Comorbidities?
Type 2 Inflammation
expert video

Type 2 Inflammatory Disease: What Are the Mechanisms that Contribute to the Development of Other Atopic Comorbidities?

Itch in Chronic Inflammatory Skin Diseases: Histaminergic and Nonhistaminergic Mechanisms and Role of IL-4 as a Central Orchestrator in Promoting Neuronal Sensitization
Type 2 Inflammation
expert video

Itch in Chronic Inflammatory Skin Diseases: Histaminergic and Nonhistaminergic Mechanisms and Role of IL-4 as a Central Orchestrator in Promoting Neuronal Sensitization

In Chronic Pruritic Skin Diseases, the Neuroimmune Axis Involves Dynamic Interactions Between Type 2 Inflammation and Sensory Nerves
Type 2 Inflammation
expert video

In Chronic Pruritic Skin Diseases, the Neuroimmune Axis Involves Dynamic Interactions Between Type 2 Inflammation and Sensory Nerves

The Effects of Chronic Spontaneous Urticaria on Mental Health and Quality of Life
Dermatology
expert video

The Effects of Chronic Spontaneous Urticaria on Mental Health and Quality of Life

Atopic Dermatitis and the Growing Evidence for Its Association with Various Non-Atopic Systemic Diseases
Dermatology
expert video

Atopic Dermatitis and the Growing Evidence for Its Association with Various Non-Atopic Systemic Diseases

Which Biomarkers of AD Might Be Robust Enough to Be Evaluated as a Measure of Disease Modification?
Dermatology
expert video

Which Biomarkers of AD Might Be Robust Enough to Be Evaluated as a Measure of Disease Modification?

From Protective Type 2 Immunity to Aberrant Type 2 Inflammation
Type 2 Inflammation
expert video

From Protective Type 2 Immunity to Aberrant Type 2 Inflammation

Underlying Type 2 Inflammation Drives a Chronic Itch-Scratch Cycle in Atopic Dermatitis
Type 2 Inflammation
expert video

Underlying Type 2 Inflammation Drives a Chronic Itch-Scratch Cycle in Atopic Dermatitis

Both Clinical and Subclinical Disease Control Are Important to Achieve Disease Modification in AD
Dermatology
expert video

Both Clinical and Subclinical Disease Control Are Important to Achieve Disease Modification in AD

Learning objectives

  • Watch soundbites on cross-disease neuroimmune pathways that sustain inflammation and itch, and how these signals relate to symptom severity and burden
  • Learn about overlapping comorbidities and quality-of-life impact across AD, PN, CSU, and BP to better understand the disease impact on patients
  • Explore practical takeaways for clinical decision-making in AD, PN, CSU, and BP, including initiation considerations, monitoring points, and outcomes that matter to patients
Tags
disease backgroundquality of lifeexpert insightsmechanism of disease
MAT-GLB-2507498 - 1.0 - 01/2026

ADVENT is a global medical education non-promotional program by Sanofi and Regeneron. This website is intended only for duly authenticated healthcare professionals in Algeria, Argentina, Australia, Austria, Bahrain, Belgium, Brazil, Bulgaria, Canada, Chile, China, Colombia, Costa Rica, Croatia, Czech Republic, Denmark, Dominican Republic, Ecuador, Egypt, Estonia, Finland, France, Germany, Greece, Guatemala, Hong Kong, Hungary, Iceland, India, Israel, Italy, Japan, Kuwait, Latvia, Lebanon, Lithuania, Macau, Malaysia, Norway, Oman, Panama, Peru, Poland, Portugal, Qatar, Romania, Saudi Arabia, Singapore, Slovenia, South Africa, South Korea, Spain, Sudan, Sweden, Switzerland, Taiwan, Thailand, The Netherlands, Turkey, United Arab Emirates, or the United States of America.

For healthcare professionals in Algeria: Please read the additional Terms of Use.

Sanofi | Regeneron Logo

© 2025 Sanofi and Regeneron Pharmaceuticals, Inc.

All rights reserved.
MAT-GLB-2302957 - 4.0 - 10/2025

All Rights Reserved.

Sanofi and Regeneron are global leaders in pharmaceutical development, each with a long history of supporting frontline physicians to improve human health and reduce the burden of disease. Driven by the same commitment to patients and their families, Sanofi and Regeneron have partnered to take on type 2 inflammation and the range of chronic conditions in which excessive inflammation plays a role.

Country/region: BrazilChange country/region